The effect of hydroxychloroquine against SARS-CoV-2 infection in rheumatoid arthritis patients
Küçükakkaş et al.
, The effect of hydroxychloroquine against SARS-CoV-2 infection in rheumatoid arthritis patients
, Research Square, doi:10.21203/rs.3.rs-43812/v1 (Preprint)
Retrospective 17 rheumatoid arthritis COVID-19+ patients, 7 on HCQ treatment, showing no significant differences. They study reports only including hospitalized patients, but the results include non-hospitalized patients. Results do not reflect potential difference in the probability that a case is serious enough to have been tested and identified. Few group details are provided (even the age of patients in each group is not specified).
This study is excluded in the after exclusion results of meta
minimal details of groups provided.
risk of ICU admission, 42.9% higher, RR 1.43, p = 1.00, treatment 1 of 7 (14.3%), control 1 of 10 (10.0%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Küçükakkaş et al., 20 Jul 2021, retrospective, Turkey, preprint, 2 authors.
Abstract: The effect of hydroxychloroquine against SARSCoV-2 infection in rheumatoid arthritis patients
Okan Küçükakkaş ( firstname.lastname@example.org )
Bezmialem Vakıf University https://orcid.org/0000-0001-6971-4229
Bezmialem Vakıf University https://orcid.org/0000-0002-0902-6771
Keywords: SARS-CoV-2, hydroxychloroquine, rheumatoid arthritis, prophylaxis, treatment
License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
INTRODUCTION: The effectiveness of hydroxychloroquine in SARS-CoV-2 prophylaxis and treatment is
still controversial. In this study, our aim is to investigate the potential effects of hydroxychloroquine
therapy on patients with diagnosed with rheumatoid arthritis and a con rmed SARS-CoV-2 infection.
METHOD: We included patients who were followed up with a diagnosis of rheumatoid arthritis and whose
SARS-CoV-2 infection was con rmed. The patients were divided into two groups as those who previously
used hydroxychloroquine and those who did not, and were compared in terms of clinical and laboratory
RESULTS: Our study included 17 patients with adequate data (2 males, 15 females). The mean age of the
patients was 57.2 ± 11.6 years. 7 (41.2%) patients were receiving hydroxychloroquine regularly for the
last 6 months. When the effect of hydroxychloroquine on clinical and laboratory parameters of patients
was examined, there was no signi cant difference between the groups of patients using and not using
hydroxychloroquine. The patients using and not using hydroxychloroquine were compared for the
presence of typical SARS-CoV-2 infection ndings on computed tomography images, admission to the
hospital and intensive care. No signi cant differences were observed between these two groups.
CONCLUSIONS: Many studies on the effectiveness of hydroxychloroquine use in SARS-CoV-2 infection
are still ongoing. Due to its importance in rheumatology practice, it is very important to clarify the position
of hydroxychloroquine in SARS-CoV-2 therapy. Our ndings suggest that having previously used
hydroxychloroquine does not have any negative or positive effect on the infection.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.